New draft guidance from the FDA has opened the door for the development of insulin biosimilars, potentially allowing for cheaper near-identical versions of these biologic drugs to be interc
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
